GRCL Gracell Biotechnologies Inc

 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 15

 

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER

SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION

OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934.

 

Commission File Number 001-39838

 

GRACELL BIOTECHNOLOGIES INC.

(Exact name of registrant as specified in its charter)

 

Building 12, Block B, Phase II

Biobay Industrial Park

218 Sangtian St. 

Suzhou Industrial Park, 215123

People’s Republic of China

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

American depositary shares (one American depositary share representing five ordinary shares, par value

US$0.0001 per share)

 

Ordinary shares, par value US$0.0001 per share

(Title of each class of securities covered by this Form)

 

None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

 

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

	Rule 12g-4(a)(1)	x
	Rule 12g-4(a)(2)	¨
	Rule 12h-3(b)(1)(i)	x
	Rule 12h-3(b)(1)(ii)	¨
	Rule 15d-6	¨
	Rule 15d-22(b)	¨

 

 

Approximate number of holders of record as of the certification or notice date: One.

 

Pursuant to the requirements of the Securities Exchange Act of 1934, Gracell Biotechnologies Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

	Gracell Biotechnologies Inc.
Date: March 4, 2024	By:	/s/ David E. White
	Name:	David E. White
	Title:	Director

 

 

---